Comparison of transforming growth factor beta and a human tumour-derived suppressor factor
- PMID: 2059965
- PMCID: PMC11038515
- DOI: 10.1007/BF01744940
Comparison of transforming growth factor beta and a human tumour-derived suppressor factor
Abstract
Serum-free supernatants from the human melanoma cell line G361 contain a factor that can potently suppress the generation of tumouricidal lymphokine-activated killer (LAK) cells in response to interleukin-2. To characterise the suppressive factor of tumour origin we performed a number of physicochemical and functional comparisons with another immunosuppressive protein, transforming growth factor beta (TGF beta). The bioactivity of tumour-derived suppressor factor (TDSF), assayed by suppression of LAK cell generation, was unaffected by a reducing agent but lost when denatured with a chaotropic agent. In contrast, TGF beta was inactivated by reduction but not denaturation. TDSF lost bioactivity in conditions of pH less than 4, whereas TGF beta showed no loss of activity. The TDSF moiety has an estimated pI of 4.3 and a molecular mass of 69-87 kDa. This differs from published values of pI 9.5, and 25 kDa molecular mass for TGF beta. Anti-TGF beta antiserum reversed the effects of TGF beta but did not affect the suppression of LAK cell generation caused by TDSF. These findings provide compelling evidence that the TDSF moiety is not TGF beta, and may be a novel immunoregulatory cytokine.
Similar articles
-
Transforming growth factor beta 1 (TGF-beta 1) produced in tumour tissue after chemotherapy acts as a lymphokine-activated killer attractant.Br J Cancer. 1996 Jul;74(2):274-9. doi: 10.1038/bjc.1996.351. Br J Cancer. 1996. PMID: 8688335 Free PMC article.
-
Generation of lymphokine-activated killer cells in human ovarian carcinoma ascitic fluid: identification of transforming growth factor-beta as a suppressive factor.Cancer Immunol Immunother. 1991;32(5):296-302. doi: 10.1007/BF01789047. Cancer Immunol Immunother. 1991. PMID: 1998971 Free PMC article.
-
Suppression of lymphokine-activated killer (LAK) cell induction mediated by interleukin-4 and transforming growth factor-beta 1: effect of addition of exogenous tumour necrosis factor-alpha and interferon-gamma, and measurement of their endogenous production.Clin Exp Immunol. 1990 Dec;82(3):583-9. doi: 10.1111/j.1365-2249.1990.tb05494.x. Clin Exp Immunol. 1990. PMID: 2124961 Free PMC article.
-
The glioblastoma-derived T-cell suppressor factor/transforming growth factor beta 2 inhibits the generation of lymphokine-activated killer (LAK) cells.Int J Cancer. 1988 Oct 15;42(4):562-7. doi: 10.1002/ijc.2910420416. Int J Cancer. 1988. PMID: 3262591
-
Lymphokine-activated killer lymphocytes: evidence for regulation of induction and function by multiple cytokines.Immunol Ser. 1989;48:19-35. Immunol Ser. 1989. PMID: 2488321 Review. No abstract available.
Cited by
-
Expression of a suppressive p15E-related epitope in colorectal and gastric cancer.Br J Cancer. 1993 Sep;68(3):610-6. doi: 10.1038/bjc.1993.395. Br J Cancer. 1993. PMID: 7688979 Free PMC article.
References
-
- Anzano MA, Rieman D, Pritchett W, Bowen-Pope DF, Greig R. Growth factor production by human colon carcinoma cell lines. Cancer Res. 1989;49:2898. - PubMed
-
- Assoian RK, Komoriya A, Meyers CA, Miller DM, Sporn MB. Transforming growth factor-beta in human platelets; identification of a major storage site, purification and characterization. J Biol Chem. 1983;258:7155. - PubMed
-
- DeFries RU, Golub SH. Characteristics and mechanism of IFN-gamma induced protection of human tumor cells from lysis by lymphokine-activated killer cells. J Immunol. 1988;140:3686. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous